Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :482
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded583    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


Year : 2011  |  Volume : 48  |  Issue : 2  |  Page : 158-164

Management of primary and metastatic triple negative breast cancer: Perceptions of oncologists from India

1 Indian Co-operative Oncology Network, Mumbai, India
2 Tata Memorial Hospital, Mumbai, India
3 Bombay Hospital, Mumbai, India
4 Leelavati Hospital, Mumbai, India
5 Sanofi Aventis, Mumbai, India
6 BP Poddar Hospital, Kolkata, India
7 Advanced Medical and Research Center, Kolkata, India
8 Apollo Glenagles Hospital, Kolkata, India
9 Dayanand Medical College, Ludhiana, India
10 Birla Cancer Center, Jaipur, India
11 Jehangir Hospital, Pune, India
12 CMC, Vellore, India
13 Kidwai Memorial Institute of Oncology, Bangalore, India
14 Apollo Speciality Hospital, Chennai, India
15 Meedanta Hospital, Gurgaon, NCR, India
16 Rajiv Gandhi Cancer Institute, India
17 Apollo Hospital, India

Correspondence Address:
P M Parikh
Indian Co-operative Oncology Network, Mumbai
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-509X.82874

Rights and Permissions

Background: In order to document the understanding of current evidence for the management of triple negative breast cancer and application of this knowledge in daily practice, we conducted an interactive survey of practicing Indian oncologists. Materials and Methods: A core group of academic oncologists devised two hypothetical triple negative cases (metastatic and early breast cancer, respectively) and multiple choice options under different clinical circumstances. The respondents were practicing oncologists in different Indian cities who participated in either an online survey or a meeting. The participants electronically chose their preferred option based on their everyday practice. Results: A total of 152 oncologists participated. Just over half (53.8%) preferred taxane based chemotherapy as first-line chemotherapy in the metastatic setting. In the adjuvant setting, a taxane regimen was chosen by 61%. Over half of respondents (52.6%) underestimated the baseline survival of a patient with node positive triple-negative tumor and 18.9% overestimated this survival compared to the estimate of the Adjuvant! program. Discussion: This data offers insight into the perceptions and practice of a diverse cross-section of practicing oncologists in India with respect to their therapeutic choices in metastatic and adjuvant settings in triple negative breast cancer.


Print this article     Email this article

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  © 2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow